Potential Kidney Protection with Liraglutide and Semaglutide: Exploratory Mediation Analysis.

Johannes F. E. Mann,John B. Buse,Thomas Idorn,Lawrence A. Leiter,Richard E. Pratley,Soren Rasmussen,Tina Vilsboll,Benjamin Wolthers,Vlado Perkovic

Carolina Digital Repository (University of North Carolina at Chapel Hill)（2021）

引用 29|浏览8

暂无评分

摘要

To investigate whether effects on chronic kidney disease risk factors could explain the apparent reduction in kidney outcomes (composite of macroalbuminuria, doubling of serum creatinine, renal replacement therapy, or renal death), primarily driven by changes in albuminuria, after treatment with the glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) liraglutide and semaglutide in patients with type 2 diabetes in the LEADER and SUSTAIN 6 trials.

查看译文

关键词

chronic kidney disease,glucagon-like peptide-1 receptor agonist,kidney mediation,liraglutide,semaglutide,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要